Michel Delforge

8PUBLICATIONS
53CO-AUTHORS
Ngā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 24, 2026
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

|Apr 27, 2026
Belgian recommendations for tissue diagnosis of amyloidosis.

|Jan 21, 2026
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?

Finn Segers, Michel Delforge

|Mar 24, 2025
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.

Jill Corre, Laure Vincent, Philippe Moreau

|Feb 10, 2025
Suspect the unexpected: proliferative glomerulonephritis with monoclonal immunoglobulin deposits and a negative hematological work-up. A case of monoclonal gammopathy of renal significance.

Benoît Delforge, Elien Mahieu, Amélie Dendooven

|Mar 10, 2017
How I manage the toxicities of myeloma drugs.

Michel Delforge, Heinz Ludwig

Pageof 2

Frequent Collaborators

3 joint publications

Amélie Dendooven

3 joint publications

Xavier Leleu

3 joint publications

Aurore Perrot

3 joint publications

Sonja Zweegman